Remove 2029 Remove Disease Remove Research
article thumbnail

Calico and Broad Institute extend collaboration, adding focus on age-related neurodegeneration

Broad Institute

Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery.

article thumbnail

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

The Pharma Data

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About LATTICE-UC. About Ulcerative Colitis.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is the largest CRO in the US?

Vial

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. ’s services include supporting life sciences research, analytical solutions, and diagnostics or developing and manufacturing therapeutic interventions. from 2024 to reach US$129.8

article thumbnail

Genomics/Biobanks/Cohort Studies

Broad Institute

The Sabatini Lab focuses on the development and regulation of synapses in the brain and the relationship of these processes to behavior and disease. at Harvard University in 2029, where he is pursuing a PhD in Economics and Health Policy. Helsinki Center of Economic Research, Helsinki 2013). hypertension, diet quality).

article thumbnail

BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

The Pharma Data

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

BY LAURA DIANGELO, MPH | JAN 30, 2024 10:25 AM CST Diagnostic regulation: A quick overview Diagnostics products are those intended to identify, signal or detect a specific health condition, infection or disease, or monitor a person’s health or health status. Featuring previous research and expert analysis by Corey Jaseph. In the U.S.,

FDA 40